Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Thorac Cardiovasc Surg. 2015 Oct 19;151(4):969–979.e3. doi: 10.1016/j.jtcvs.2015.09.127

Table 3. Univariable Cox models for Overall Survival and Disease-Free Survival Analyses.

Overall Survival Disease-Free Survival
HR 95% CI P HR 95% CI P
Post-induction PET (N2-avid v N2-negative) 1.50 0.75, 3.00 0.3 1.05 0.59, 1.86 0.9
Pathological N2 Status (N2-persistent v N2-negative) 0.98 0.54, 1.77 0.9 1.58 0.94, 2.63 0.082
Pathologic Staging (≥ypIIIA v <ypIIIA) 1.09 0.59, 1.99 0.8 1.67 0.99, 2.82 0.056
Age at Surgery 0.99 0.96, 1.03 0.6 0.97 0.94, 1.00 0.044
Male 1.49 0.82, 2.70 0.2 1.07 0.66, 1.75 0.8
Smoking, yes 1.02 0.48, 2.20 0.9 0.93 0.48, 1.78 0.8
Smoking Pack-years >30, yes 0.98 0.54, 1.75 0.9 0.71 0.43, 1.16 0.2
Pulmonary comorbidity, yes 1.07 0.55, 2.10 0.8 0.77 0.44, 1.35 0.4
Cardiac comorbidity, yes 0.95 0.48, 1.88 0.9 0.69 0.40, 1.21 0.2
NIDDM, yes 1.43 0.50, 4.09 0.5 1.73 0.68, 4.41 0.3
FEV1 (%) 0.99 0.97, 1.01 0.2 0.99 0.97, 1.00 0.10
Diffusion (%) 1.00 0.99, 1.02 0.6 1.01 1.00, 1.02 0.2
Adenocarcinoma, yes 1.07 0.52, 2.23 0.9 1.65 0.88, 3.10 0.12
EGFR, present 0.74 0.26, 2.12 0.6 0.79 0.35, 1.75 0.6
KRAS, present 1.66 0.81, 3.40 0.2 1.18 0.64, 2.20 0.6
Adjuvant Therapy
 PORT-only only vs None 1.19 0.61, 2.33 0.6 1.14 0.65, 2.01 0.6
 Adjuvant Ch-only vs None 0.64 0.26, 1.58 0.3 0.78 0.37, 1.63 0.5
 PORT+Adjuvant Ch vs None 0.60 0.17, 2.08 0.4 0.94 0.38, 2.31 0.9
Resection: R1 vs R0 2.08 0.87, 4.97 0.10 1.46 0.66, 3.22 0.3
Resection: R2 vs R0 1.33 0.41, 4.34 0.6 2.32 0.92, 5.88 0.075
Pathologic T-Stage (≥IIA v <IIA)a 1.80 0.98, 3.31 0.058 2.22 1.33, 3.73 0.002
a

Pathologic T-stage: 45 had <IIA (0, IA, IB) and 55 had ≥IIA (includes IIA, IIB, IIIA, III and IV). NIDDM = non-insulin dependent diabetes; PORT = post-operative radiation therapy; Ch = chemotherapy

PET = positron emission scan; NIDDM = non-insulin dependent diabetes; FEV1 = Forced expiratory volume in one second; EGFR = Endothelial growth factor receptor; KRAS = Kirsten rat sarcoma viral oncogene homolog; PORT = post-operative radiation therapy.